HC Wainwright Reiterates Buy Rating for BiomX (NYSEAMERICAN:PHGE)

HC Wainwright reiterated their buy rating on shares of BiomX (NYSEAMERICAN:PHGE) in a report released on Wednesday morning,Benzinga reports. They currently have a $2.00 price objective on the stock.

BiomX Stock Performance

NYSEAMERICAN:PHGE opened at $0.76 on Wednesday. BiomX has a 52 week low of $0.48 and a 52 week high of $8.55. The stock has a market cap of $13.86 million, a PE ratio of -0.24 and a beta of 1.31.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).